UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

Journal of clinical oncology, 2011-08, Vol.29 (22), p.3008-3015

2011

Volltextzugriff (PDF)

Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

Journal of clinical oncology, 2010-08, Vol.28 (22), p.3555-3561

2010

Volltextzugriff (PDF)

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

Journal of clinical oncology, 2012-02, Vol.30 (4), p.372-379

2012

Volltextzugriff (PDF)

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

Journal of clinical oncology, 2012-02, Vol.30 (4), p.362-371

2012

Volltextzugriff (PDF)

Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer

Journal of clinical oncology, 2007-02, Vol.25 (4), p.384-389

2007

Volltextzugriff (PDF)

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

Journal of clinical oncology, 2006-09, Vol.24 (26), p.4324-4332

2006

Volltextzugriff (PDF)

Prognostic DNA Methylation Biomarkers in Ovarian Cancer

Clinical cancer research, 2006-05, Vol.12 (9), p.2788-2794

2006

Volltextzugriff (PDF)

A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer

Clinical cancer research, 2014-02, Vol.20 (3), p.711-723

2014

Volltextzugriff (PDF)

ERCC5 Is a Novel Biomarker of Ovarian Cancer Prognosis

Journal of clinical oncology, 2008-06, Vol.26 (18), p.2952-2958

2008

Volltextzugriff (PDF)

Ovarian Preservation in Stage I Low-Grade Endometrial Stromal Sarcomas

Obstetrics and gynecology (New York. 1953), 2005-12, Vol.106 (6), p.1304-1308

2005

Volltextzugriff (PDF)

Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

Clinical cancer research, 2014-03, Vol.20 (5), p.1288-1297

2014

Volltextzugriff (PDF)

Genome-Wide Loss of Heterozygosity and Uniparental Disomy in BRCA1/2-Associated Ovarian Carcinomas

Clinical cancer research, 2008-12, Vol.14 (23), p.7645-7651

2008

Volltextzugriff (PDF)

Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer

International journal of cancer, 2005-12, Vol.117 (6), p.1049-1054

2005

Volltextzugriff (PDF)

Improved survival in women with BRCA‐associated ovarian carcinoma

Cancer, 2003-05, Vol.97 (9), p.2187-2195

2003

Volltextzugriff (PDF)

BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

Obstetrics and gynecology (New York. 1953), 2005-12, Vol.106 (6), p.1327-1334

2005

Volltextzugriff (PDF)

Use of CA125 and HE4 Serum Markers to Predict Ovarian Cancer in Elevated-Risk Women

Cancer epidemiology, biomarkers & prevention, 2014-07, Vol.23 (7), p.1383-1393

2014

Volltextzugriff (PDF)

AIB1 Polymorphisms Predict Aggressive Ovarian Cancer Phenotype

Cancer epidemiology, biomarkers & prevention, 2005-12, Vol.14 (12), p.2919-2922

2005

Volltextzugriff (PDF)

Interpretation of Single and Serial Measures of HE4 and CA125 in Asymptomatic Women at High Risk for Ovarian Cancer

Cancer epidemiology, biomarkers & prevention, 2012-11, Vol.21 (11), p.2087-2094

2012

Volltextzugriff (PDF)

Xeroderma pigmentosum complementation group C single‐nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression‐free survival in advanced ovarian cancer

Cancer, 2012-02, Vol.118 (3), p.689-697

2012

Volltextzugriff (PDF)

Short Androgen Receptor Allele Length Is a Poor Prognostic Factor in Epithelial Ovarian Carcinoma

Clinical cancer research, 2003-09, Vol.9 (10), p.3667-3673

2003

Volltextzugriff (PDF)

BRCA1-Associated Epigenetic Regulation of p73 Mediates an Effector Pathway for Chemosensitivity in Ovarian Carcinoma

Cancer research (Chicago, Ill.), 2010-09, Vol.70 (18), p.7155-7165

2010

Volltextzugriff (PDF)

Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

Cancer chemotherapy and pharmacology, 2012-05, Vol.69 (5), p.1135-1144

2012

Volltextzugriff (PDF)

Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures

American journal of obstetrics and gynecology, 2003-07, Vol.189 (1), p.22-27

2003

Volltextzugriff (PDF)

Pattern of Lymph Node Metastases in Clinically Unilateral Stage I Invasive Epithelial Ovarian Carcinomas

Gynecologic oncology, 2001-01, Vol.80 (1), p.56-61

2001

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Aktive Filter

ThemaFemale Genital Diseases

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(66)
Tagungsberichte
(1)

Sprache

Englisch
(67)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

Prognostic DNA Methylation Biomarkers in Ovarian Cancer

A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer

ERCC5 Is a Novel Biomarker of Ovarian Cancer Prognosis

Ovarian Preservation in Stage I Low-Grade Endometrial Stromal Sarcomas

Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

Genome-Wide Loss of Heterozygosity and Uniparental Disomy in BRCA1/2-Associated Ovarian Carcinomas

Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer

Improved survival in women with BRCA‐associated ovarian carcinoma

BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

Use of CA125 and HE4 Serum Markers to Predict Ovarian Cancer in Elevated-Risk Women

AIB1 Polymorphisms Predict Aggressive Ovarian Cancer Phenotype

Interpretation of Single and Serial Measures of HE4 and CA125 in Asymptomatic Women at High Risk for Ovarian Cancer

Xeroderma pigmentosum complementation group C single‐nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression‐free survival in advanced ovarian cancer

Short Androgen Receptor Allele Length Is a Poor Prognostic Factor in Epithelial Ovarian Carcinoma

Platinum Sensitivity-Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

BRCA1-Associated Epigenetic Regulation of p73 Mediates an Effector Pathway for Chemosensitivity in Ovarian Carcinoma

Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures

Pattern of Lymph Node Metastases in Clinically Unilateral Stage I Invasive Epithelial Ovarian Carcinomas

Aktive Filter

Suchergebnisse filtern